Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment.
Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment.
复制标题
DOI：
10.1038/s41598-020-78440-w
复制
发表时间：
2020-12-04
影响因子：
4.6
通讯作者：
Park T
中科院分区：
文献类型：
--
作者：
Kim SA;Cho EJ;Lee S;Cho YY;Kim B;Yoon JH;Park T
纤连蛋白是一种在多种肿瘤细胞中异常表达的基质糖蛋白，是肝细胞癌 (HCC) 早期诊断的已知候选生物标志物。在本研究中，我们研究了血清纤连蛋白水平是否可以预测早期 HCC 患者治愈后的肿瘤复发。共有 83 名在初步治疗后表现出完全缓解的患者被纳入。分析基线时和初始治疗后 4-6 周的血清纤连蛋白水平与复发的关系。进行多变量逻辑回归分析以构建预后列线图。基线纤连蛋白水平与肿瘤大小、数量、分期和血清甲胎蛋白水平不显着相关。然而，在多变量逻辑回归中，治疗后血清纤连蛋白水平的降低与 HCC 复发率的降低显着相关（比值比，0.009；p<0.001）。此外，由性别和血清纤连蛋白变化组成的列线图显示出预测 HCC 复发的良好判别能力，受试者工作曲线下面积为 0.87。总之，血清纤连蛋白水平的变化可能是评估早期 HCC 患者治愈后治疗反应的替代指标。
Fibronectin, a matrix glycoprotein aberrantly expressed in various tumor cells, is a known candidate biomarker for the early diagnosis of hepatocellular carcinoma (HCC). In this study, we investigated whether serum fibronectin levels could predict tumor recurrence in patients with early-stage HCC after curative treatment. A total of 83 patients who showed complete response after initial curative treatment were included. The levels of serum fibronectin at baseline and 4–6 weeks after initial treatment were analyzed with regard to their associations with recurrence. Multivariate logistic regression analyses were performed to construct a prognostic nomogram. Baseline fibronectin levels were not significantly correlated with tumor size, number, stage, and serum α-fetoprotein levels. However, decrease in serum fibronectin levels after treatment was significantly associated with reduced HCC recurrence in multivariate logistic regression (odds ratio, 0.009; p < 0.001). Furthermore, a nomogram consisting of gender and changes in serum fibronectin showed a good discriminatory capability for the prediction of HCC recurrence with an area under the receiver-operating curve of 0.87. In conclusion, changes in serum fibronectin levels may be a surrogate indicator for assessment of treatment response in patients with early HCC after curative treatment.
登录
查看更多内容
影响因子：
64.8
作者：
Clark, EA;Golub, TR;Hynes, RO
通讯作者：
Hynes, RO
影响因子：
3.6
作者：
SZENDROI, M;LAPIS, K
通讯作者：
LAPIS, K
影响因子：
10.3
作者：
JOHNSON, PJ;WILLIAMS, R
通讯作者：
WILLIAMS, R
DOI：
10.1093/jnci/93.21.1644
发表时间：
2001-11-07
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Yu, MW;Yang, YC;Chen, CJ
通讯作者：
Chen, CJ
影响因子：
3.9
作者：
Wang JP;Hielscher A
通讯作者：
Hielscher A